Flat Rate vs Dose-Based Pricing

The dose-step tax

4 of the 16 priced programmes raise your bill as the dose climbs. The increase lands exactly when the evidence says the dose is starting to work, which inverts the incentive a patient faces.

Where the crossover sits

Flat pricing is worst value at the bottom of the ladder and best at the top. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled programme may well be cheaper. The problem is that nobody knows at intake, which is why flat pricing is better understood as insurance against uncertainty than as a lower price.

The question that settles it

What will I pay at 10 mg and at 15 mg, including every fee? A flat programme answers with one number. A dose-scaled programme answers with three.

What the spread tells you

All-in cost at a 10 mg maintenance dose runs from $215 to $597 across the 16 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.8-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

Reading this against the rest of the market

The programmes named above sit inside a market where 16 routes publish a price we could capture and roughly half that number publish nothing interpretable at all. A ranking drawn only from the priced group is not the whole market; it is the part of the market willing to be compared.

That distinction matters when a programme you were recommended does not appear here. Absence usually means it does not publish, not that we judged it poorly, and its page says which.

What would change this analysis

A programme publishing a price at a dose tier currently blank. A pricing model changing in either direction. A programme leaving the compounded market, which five did during 2026. Or a correction from a reader with a source we can check.

All four are logged with the date, and the tables above regenerate from the dataset on every build rather than being edited by hand — so this page cannot quietly drift away from the underlying record.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $215 a month, $2,580 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 5 of 16. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Reading a price like a clinician would

A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?

Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.

None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.

What the GIP arm may be doing

GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.

This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.

The question worth asking before the price question

Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.

Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.